Annabel Samimy

James Sidoti

Jim Sidoti

Anthony Petrone

- Kamada projects **FY 2025 revenue** between **$178 million and $182 million** and **EBITDA** between **$40 million and $44 million**, having raised its guidance at the end of Q2.  **[1567529_tx_382208_1]** **[1567529_tx_382208_5]** 
- The company's **inhaled AAT Phase III pivotal study** is **55% to 60% recruited**, with an **efficacy futility analysis expected by the end of 2025**.  **[1567529_tx_382208_4]** **[1567529_tx_382208_5]**  Kamada intends to partner this product commercially.  **[1567529_tx_382208_7]** 
- Kamada has opened **two new plasma collection centers** that are expected to generate **$8 million to $10 million in additional annual revenue**.  **[1567529_tx_382208_2]** 
- The company paid its **first dividend** earlier this year and may continue this practice based on profitability and cash availability.  **[1567529_tx_382208_2]**

KAMADA (KMDA)